Literature DB >> 7639800

Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity.

H Suzuki1, H Takemura, H Kashiwagi.   

Abstract

OBJECTIVE: To evaluate the relationship between the serum concentration of interleukin-1 receptor antagonist (IL-1Ra) and systemic lupus erythematosus (SLE) disease activity, and to investigate the expression of IL-1Ra messenger RNA (mRNA) and its production by monocytes from patients with SLE.
METHODS: Serum IL-1Ra was measured by enzyme-linked immunosorbent assay, and expression of IL-1Ra mRNA was determined by Northern blotting.
RESULTS: Serum IL-1Ra concentrations were significantly higher in patients with active SLE compared with normal subjects and patients with other rheumatic diseases, and showed a strong correlation with SLE disease activity. IL-1Ra mRNA expression in freshly isolated monocytes from patients with active SLE was considerably higher than that in normal monocytes. Moreover, monocytes from patients with active SLE produced increased amounts of IL-1Ra in response to adherent IgG, compared with monocytes from normal subjects.
CONCLUSION: A high serum concentration of IL-1Ra is a pathophysiologic feature of active SLE and a good indicator of disease activity. Functional changes of monocytes, such as increased secretion of IL-1Ra in response to adherent IgG and enhanced expression of IL-1Ra mRNA in freshly isolated cells, may be involved in the enhanced IL-1Ra production in active SLE. High concentrations of IL-1Ra in the circulation and possibly in peripheral lymphoid tissues may influence immunologic and inflammatory features of SLE.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639800     DOI: 10.1002/art.1780380806

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice.

Authors:  Run-Zhi Zhu; Di Xiang; Chao Xie; Jing-Jing Li; Jian-Jun Hu; Hong-Lin He; Yun-Sheng Yuan; Jin Gao; Wei Han; Yan Yu
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.

Authors:  C Gabay; M F Smith; D Eidlen; W P Arend
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

3.  Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?

Authors:  E R Capper; J K Maskill; C Gordon; A I F Blakemore
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

4.  The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.

Authors:  Seth G Thacker; Celine C Berthier; Deborah Mattinzoli; Maria Pia Rastaldi; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

Review 5.  Anticytokine therapies in systemic lupus erythematosus.

Authors:  Antonio La Cava
Journal:  Immunotherapy       Date:  2010-07       Impact factor: 4.196

6.  Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.

Authors:  Sebastian Niedźwiecki; Tomasz Stepień; Krzysztof Kuzdak; Henryk Stepień; Roman Krupiński; Daniel Seehofer; Nada Rayes; Frank Ulrich
Journal:  Langenbecks Arch Surg       Date:  2007-12-07       Impact factor: 3.445

7.  Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease.

Authors:  Nurşen Düzgün; Ergin Ayaşlioğlu; Hüseyin Tutkak; Olcay T Aydintuğ
Journal:  Rheumatol Int       Date:  2003-11-05       Impact factor: 2.631

8.  Interleukin-1 gene cluster and IL-1 receptor polymorphisms in Iranian patients with systemic lupus erythematosus.

Authors:  Zahra Tahmasebi; Mahmoud Akbarian; Sedigheh Mirkazemi; Abtin Shahlaee; Zahra Alizadeh; Ali Akbar Amirzargar; Ahmad Reza Jamshidi; Shima Ghoroghi; Shiva Poursani; Keramat Nourijelyani; Mahdi Mahmoudi
Journal:  Rheumatol Int       Date:  2013-05-31       Impact factor: 2.631

9.  Biological therapy in systemic lupus erythematosus.

Authors:  Mariana Postal; Lilian Tl Costallat; Simone Appenzeller
Journal:  Int J Rheumatol       Date:  2012-01-30

10.  Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility.

Authors:  Andreas Jönsen; Anders A Bengtsson; Gunnar Sturfelt; Lennart Truedsson
Journal:  Arthritis Res Ther       Date:  2004-09-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.